Cronos Group Shares Up After Reporting 22% Rise In Q3 Revenue,

Zinger Key Points
  • CEO cites Canadian market growth in pre-rolls, flower, and edibles as a key revenue driver.
  • Company's robust balance sheet boasts $840 million, signaling strong financial health amidst challenges in Israel..

Toronto-based Cronos Group Inc CRON CRON announced its 2023 third-quarter financial results on Wednesday.

Despite operational challenges, including a strategic exit from U.S. hemp-derived CBD operations and geopolitical unrest affecting its Israeli market, Cronos reported a gross profit of $4.0 million in Q3 2023, a 26% increase from the same period last year.

Mike Gorenstein, the company's chairman, president and CEO referred to their Q3 2023 financial metrics as "one of the best quarters in Cronos history."

Q3 2023 Financial Highlights

  • The company reported a net revenue of $24.8 million in Q3 2023, increased by $4.4 million from Q3 2022.
  • Net loss of $1.59 million in Q3 2023 represented a 95% improvement compared to the $33.1 million reported in the same quarter of 2022.
  • Adjusted EBITDA for the quarter showed an improvement with a loss of $15.2 million, bettering by $3.3 million from the previous year.
  • Gross profit of $4.0 million in Q3 2023 increased by $0.8 million from Q3 2022.
  • Balance sheet reported $840 million in cash and short-term investments. 

Gorenstein also provided some insight into operational results. "We achieved our highest net revenue for continuing operations on record at $24.8 million, up 22% year-over-year," he said. The top-line was propelled by 40% growth year-over-year in Canada, driven by strength in pre-rolls, flower and edibles," he said. 

Cronos' CEO also highlighted strategic expansions, including recent launches in Germany and Canada.

Geopolitical Impact

"The positive results this quarter were overshadowed by the horrific and despicable events that took place in Israel, our second largest operating market," continued Gorenstein, as geopolitical unrest in Israel, its second-largest operating market, cast a shadow over the quarter. 

Price Action

Cronos' shares were trading 1.85% higher at $1.925 per share at the time of this writing around 12 noon on Wednesday.

Related News

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsEarnings Beats
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.